Moderna Reports First Quarter 2024 Financial Results and Pro

Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billionInitiated three new clinical studies evaluating Moderna's investigational...

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Brazil , Japan , Lavina Talukdar , Merck Keytruda , Chris Ridley , Sanofi Pasteur , Response Authority , Company Accolade , Eu Health Emergency , Ministry Of Health , Twitter , Instagram , European Union , Facebook , Development Expenses , Moderna Inc , Exchange Commission , Merck Sharp Dohme Corp , Linkedin Top Companies , Youtube , Blackstone Life Sciences , Nasdaq , Linkedin , Vaccines Day , Chief Executive Officer , Generation Bio , Life Edit , Administrative Expenses , Per Share , Upcoming Late Stage Pipeline , Neoantigen Therapy , Vaccines Day Investor Event , Moderna Annual Meeting , Analyst Event , Months Ended March , Merck Sharp , Private Securities Litigation Reform Act , Annual Report , Global Media , Vice President ,